Claims for Patent: 9,512,216
✉ Email this page to a colleague
Summary for Patent: 9,512,216
Title: | Use of TNF.alpha. inhibitor |
Abstract: | The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. |
Inventor(s): | Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Taylor; Lori K. (Boston, MA), Chartash; Elliot K. (Marietta, GA), Yan; Philip (Vernon Hills, IL), Granneman; George R. (Marco Island, FL) |
Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 15/173,191 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,512,216 |
Patent Claims: | 1. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque
psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 75 response at week 12 of the
treatment.
2. The method of claim 1, wherein at least 5% body surface area (BSA) of the patient is affected by the moderate to severe chronic plaque psoriasis. 3. The method of claim 1, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 4. The method of claim 1, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 5. The method of claim 3, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 6. The method of claim 2, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 7. The method of claim 2, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 8. The method of claim 6, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 9. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing. 10. The method of claim 9, wherein at least 5% body surface area (BSA) of the patient is affected by the moderate to severe chronic plaque psoriasis. 11. The method of claim 9, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 12. The method of claim 9, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 13. The method of claim 11, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 14. The method of claim 10, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 15. The method of claim 10, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 16. The method of claim 15, wherein adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. |
Details for Patent 9,512,216
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2021-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.